Good morning everyone,
My father (68 yr) was diagnosed with PC in June 2023 de novo (stage IV, Gleason 9, mets to lymph nodes and spine, PSA of 800+ng/mL). He started hormone therapy immediately, then completed 6 rounds of docetaxel chemotherapy, and has been on Darolutamide (Nubeqa) since Aug 2023. His response to treatment was great and his PSA dropped from 800 ng/mL to its lowest which was 0.1 ng/ML which he achieved in October 2024.
Unfortunately, in February 2025 we got news that his PSA jumped up to 3.43 ng/ML. He completed scans which showed that his bone mets had progressed, particularly around this thoracolumbar vertebra. Dad has also been experiencing increased back and hip pain since the beginning of February, particularly at night. After a recent meeting with his oncologist, the plan is to continue taking Darolutamide and HT injections, and to start a new chemotherapy called Cabazitaxel (Jevtana) on April 1, 2025.
We are still in a bit of shock as we were not expecting Darolutamide/HT Therapy to start failing only 18 months after starting. In any event, I am posting here today to kindly ask for any advice/support from people who have experience with a similar timeline to my dad's - also anyone's experience with Jevtana chemotherapy once they have progressed to CRPC. I am anxious, as it seems that castrate resistant prostate cancer does not always have a very favourable prognosis.
Regards,
Johnny
